Artiva Biotherapeutics, Inc. (ARTV) AI Stock Analysis

• Market Cap: $68.95M
• Dividend Yield: N/A
• Average Volume (3M): 307.64K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.96
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: 96
• Sector: Healthcare
• Sector Strength: 39
• Industry: Biotechnology
• EPS (TTM): -0.83
• Shares Outstanding: 24,363,120
• 10 Day Avg. Volume: 209,349
• 30 Day Avg. Volume: 307,642
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: -1.14
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: 1.09
• 1Y Price Target: $16.00
• Price Target Upside: 465.37% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 4

• Rating: 50 Neutral
• Price Target: $3.00 ▲(6.01%Upside)

Artiva Biotherapeutics' stock score is primarily driven by its financial performance challenges, despite positive technical momentum. The negative valuation metrics reflect ongoing profitability issues, while technical indicators suggest some bullish investor sentiment.

Positive Factors

Financial Position

The company is well-positioned financially, having reported a strong cash position that could fund operations into 2027, encompassing key clinical data milestones.

Product Development

Artiva's primary asset, AB-101, has potential to establish itself as a safe, efficacious, and outpatient-accessible treatment for various B-cell driven autoimmune diseases.

Regulatory Approval

AlloNK received FDA fast track designation for the treatment of lupus nephritis combined with RTX/OBI, which is viewed favorably as it will streamline clinical development and regulatory interactions.

Negative Factors

Market Competition

Manufacturers flooded the SLE/LN space to replicate Schett's autoimmune reset, creating enrollment changes and generating small datasets across indications that don't live up to the initial bar set by Schett.

Market Uncertainty

The target price is being adjusted to reflect broader market uncertainty.

Regulatory Changes

Management commented that recent changes in CBER are not a positive.

Artiva Biotherapeutics, Inc. Business Overview & Revenue Model

Company Description

Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma. It also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell product candidate; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate. The company was incorporated in 2019 and is headquartered in San Diego, California.

How the Company Makes Money

Artiva Biotherapeutics generates revenue primarily through partnerships, collaborations, and licensing agreements with pharmaceutical and biotechnology companies. These partnerships often involve upfront payments, milestone payments, and royalties based on the successful development and commercialization of NK cell therapies. Additionally, Artiva may receive funding from research grants and government contracts to support its R&D efforts. The company's revenue model is dependent on advancing its therapeutic candidates through clinical trials, achieving regulatory approvals, and ultimately bringing its products to market, either independently or through strategic alliances.

Artiva Biotherapeutics, Inc. Financial Statement Overview

Summary

Artiva Biotherapeutics, Inc. shows revenue growth and improved equity, yet struggles with significant net losses and negative cash flow. The financial position is weak due to high debt levels and reliance on external financing.

Income Statement

Artiva Biotherapeutics, Inc. has demonstrated significant revenue growth from $2,002,000 in 2021 to $251,000 in 2024, indicating a positive trajectory. However, the company is still facing substantial net losses, with a net profit margin of -232.9% in 2024. The EBIT and EBITDA margins are also negative, reflecting ongoing operational challenges.

Balance Sheet

The balance sheet shows improvement in stockholders' equity, moving from negative to positive in 2024, but the company still has a high debt-to-equity ratio due to previous negative equity. The equity ratio improved to 89.1% in 2024, showing enhanced financial stability despite previous challenges.

Cash Flow

Cash flow analysis indicates difficulties in generating positive free cash flow, with a free cash flow of -$55.7 million in 2024. The operating cash flow to net income ratio is negative, pointing to challenges in converting earnings to cash. There is a growth in financing cash flow, reflecting reliance on external funding.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	251.00K	33.49M	4.93M	2.00M	0.00
Gross Profit	251.00K	33.49M	4.93M	2.00M	0.00
EBITDA	-64.85M	-28.41M	-58.67M	-71.58M	-17.72M
Net Income	-58.49M	-27.70M	-58.39M	-71.83M	-17.99M
Balance Sheet
Total Assets	209.58M	105.11M	133.05M	169.93M	29.23M
Cash, Cash Equivalents and Short-Term Investments	185.43M	76.97M	102.53M	160.92M	25.44M
Total Debt	14.35M	16.91M	19.45M	1.74M	2.12M
Total Liabilities	22.94M	267.13M	273.75M	258.78M	50.80M
Stockholders Equity	186.64M	-162.01M	-140.70M	-88.86M	-21.57M
Cash Flow
Free Cash Flow	-55.67M	-50.69M	-57.13M	-17.03M	-13.82M
Operating Cash Flow	-55.03M	-47.43M	-50.83M	-15.30M	-13.54M
Investing Cash Flow	-120.46M	-25.98M	-6.30M	-1.72M	-284.00K
Financing Cash Flow	162.23M	24.39M	-1.26M	152.75M	37.40M

Artiva Biotherapeutics, Inc. Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 2.83
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ARTV, the sentiment is Neutral. The current price of 2.83 is above the 20-day moving average (MA) of 2.53, above the 50-day MA of 2.11, and below the 200-day MA of 5.71, indicating a neutral trend. The MACD of 0.31 indicates Negative momentum. The RSI at 57.73 is Neutral, neither overbought nor oversold. The STOCH value of 42.67 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for ARTV.

Artiva Biotherapeutics, Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.38B	0.34	-69.01%	2.37%	16.35%	0.39%
CUE	51 Neutral	$55.55M	―	-221.66%	―	13.83%	37.66%
KRON	51 Neutral	$53.65M	―	-59.49%	―	21.15%	46.44%
ARTV	50 Neutral	$68.95M	―	-68.14%	―	―	―
GANX	46 Neutral	$49.78M	―	-290.21%	―	-100.00%	44.28%
STTK	42 Neutral	$35.07M	―	-71.90%	―	69.65%	27.98%
IMRX	27 Underperform	$121.27M	―	-102.48%	―	―	-7.78%

Artiva Biotherapeutics, Inc. Corporate Events

Artiva Biotherapeutics Approves Equity Plan Amendment

On June 24, 2025, Artiva Biotherapeutics, Inc. held its Annual Meeting of Stockholders where key decisions were made, including the approval of an amendment to the 2024 Equity Incentive Plan to increase the number of shares authorized for issuance by 1,214,580. Additionally, Daniel Baker, Ph.D., was elected as a Class I director for a three-year term, and KPMG LLP’s appointment as the independent registered public accounting firm for the fiscal year ending December 31, 2025, was ratified. These decisions are expected to impact the company’s operational strategy and governance structure.

The most recent analyst rating on (ARTV) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on Artiva Biotherapeutics, Inc. stock, see the ARTV Stock Forecast page.